More American teenagers now use the weight-loss drug Wegovy, as doctors and families grow more comfortable with the treatment ...

A study, which was published in The New England Journal of Medicine, found that tirzepatide (Zepbound) is more effective for ...

A new study brings into focus the relationship between diabetic GLP-1 users and the elevated risk of age-related eye disease.

NVO advances obesity pipeline with CagriSema and Amycretin while expanding through major deals amid rising competition.

A new report from health data firm Truveta shows there was 50 per cent increase in American teenagers using the weight-loss drug Wegovy, particularly those living with obesity.

I've been a Novo Nordisk bull for quite some time now, and I wouldn't be as spooked by the situation. Here's why. Novo Nordisk got a two-year-plus head start in the white-hot obesity drugs market, ...

A new clinical trial has revealed that tirzepatide (Zepbound) surpasses semaglutide (Wegovy) in promoting weight loss among ...

The European Medicines Agency’s safety committee said on Friday Novo Nordisk’s popular weight-loss and diabetes drugs Wegovy ...

Participants who are taking GLP-1 medications and have taken them for at least 3 months are needed for a study on eating behavior.

Excess body weight can raise the risk of certain cancers, leading researchers to wonder whether blockbuster drugs like Wegovy, Ozempic ...